lerociclib
NDA- Indications
- HR+/HER2- breast cancer
Company intelligence / Profile preview
Genor Biopharma
Shanghai, Shanghai, Chinagenorbio.com ↗
- Ownership
- Public · 6998
- Employees
- ~800
- Development stage
- Commercial
01
Overview
Genor Biopharma has multiple products on the market in China including Herceptin biosimilar (汉曲优/Hanquyou) for HER2+ breast cancer. The company has a robust pipeline of biosimilars and novel biologics in various stages of development from preclinical to commercial.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Monoclonal antibodiesFusion proteinsRecombinant proteinsBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Walvax BiotechnologySunshine Guojian PharmaceuticalI-Mab Biopharma
Beyond the preview
Go deeper on Genor Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genor Biopharma.